ATE297731T1 - Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol - Google Patents

Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol

Info

Publication number
ATE297731T1
ATE297731T1 AT99911307T AT99911307T ATE297731T1 AT E297731 T1 ATE297731 T1 AT E297731T1 AT 99911307 T AT99911307 T AT 99911307T AT 99911307 T AT99911307 T AT 99911307T AT E297731 T1 ATE297731 T1 AT E297731T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
treatment
clioquinol
metal chelators
Prior art date
Application number
AT99911307T
Other languages
English (en)
Inventor
Ashley L Bush
Xudong Huang
Craig S Atwood
Rudolph E Tanzi
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE297731T1 publication Critical patent/ATE297731T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT99911307T 1998-03-11 1999-03-11 Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol ATE297731T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/038,154 US6323218B1 (en) 1998-03-11 1998-03-11 Agents for use in the treatment of Alzheimer's disease
PCT/US1999/005291 WO1999045907A2 (en) 1998-03-11 1999-03-11 Metal chelators for use in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE297731T1 true ATE297731T1 (de) 2005-07-15

Family

ID=21898356

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99911307T ATE297731T1 (de) 1998-03-11 1999-03-11 Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol

Country Status (9)

Country Link
US (2) US6323218B1 (de)
EP (1) EP1061923B1 (de)
JP (1) JP2002506020A (de)
AT (1) ATE297731T1 (de)
AU (1) AU752236B2 (de)
CA (1) CA2323458C (de)
DE (1) DE69925816T2 (de)
HK (1) HK1033907A1 (de)
WO (1) WO1999045907A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743771B2 (en) * 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US7045531B1 (en) * 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
EP1115389B1 (de) 1998-09-25 2014-03-12 PhilERA New Zealand Limited Antagonisten und agonisten der fructosamin oxidase
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
US20040110722A1 (en) * 1999-05-27 2004-06-10 Ornberg Richard L. Modified hyaluronic acid polymers
EP1185312B1 (de) * 1999-05-27 2005-03-23 Monsanto Company Biomaterialien, modifiziert mit superoxid-dismutase imitatoren
AUPQ180499A0 (en) * 1999-07-23 1999-08-19 Biomolecular Research Institute Limited Beta-amyloid peptide inhibitors
EP1222566A1 (de) * 1999-09-23 2002-07-17 Chroma Graphics, Inc. Verfahren und vorrichtung zum beschreiben und simulieren komplexer systeme
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
WO2003077901A1 (en) 2002-03-08 2003-09-25 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
DE10221052A1 (de) * 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
US6855340B2 (en) * 2002-05-24 2005-02-15 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US20070248689A1 (en) * 2002-05-24 2007-10-25 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
WO2004007673A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Neuronal gene expression patterns
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
CN1774445A (zh) * 2002-08-16 2006-05-17 惠氏公司 用于治疗rage相关病症的组合物和方法
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
CN1774267A (zh) * 2003-01-22 2006-05-17 综合医院有限公司 与淀粉样物质结合的金属螯合剂
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
KR101008052B1 (ko) * 2003-11-12 2011-01-13 리도 케미칼 가부시키가이샤 경피흡수형 뇌 보호제
WO2005058294A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
ES2449066T3 (es) 2004-07-19 2014-03-18 Philera New Zealand Limited Síntesis de trietilentetraminas
EP1781700B1 (de) 2004-08-03 2014-03-19 TransTech Pharma, LLC Rage-fusionsproteine und anwendungsverfahren
KR20070057818A (ko) * 2004-08-03 2007-06-07 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
JP2008515805A (ja) * 2004-10-04 2008-05-15 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病のための化合物
KR20070111503A (ko) * 2005-01-31 2007-11-21 도꾸리쯔교세이호징 리가가쿠 겐큐소 탈과립화 반응 및 사이토카인 제조의 제어를 위한 작용제
WO2007055598A1 (en) * 2005-11-09 2007-05-18 Protemix Corporation Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
ES2431632T3 (es) * 2005-12-23 2013-11-27 Gcoder Systems Ab Patrón de posicionamiento
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
US20130178536A1 (en) * 2006-04-25 2013-07-11 Stc.Unm Substituted cis- and trans-stilbenes as therapeutic agents
EP2380983A3 (de) 2006-05-05 2012-12-05 TransTech Pharma Inc. RAGE-Fusionsproteine, Formulierungen daraus und Verfahren zu ihrer Verwendung
US8338089B2 (en) * 2006-11-20 2012-12-25 The Johns Hopkins University Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
JP5706688B2 (ja) 2007-06-14 2015-04-22 ギャラクティカ ファーマシューティカルズ， インク． Ｒａｇｅ融合タンパク質
US20090131857A1 (en) * 2007-11-20 2009-05-21 Mark Geiger Method and apparatus for introducing a medicinal dose directly into a mammalian patient's cerebrospinal fluid
WO2010122460A1 (en) 2009-04-20 2010-10-28 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011041198A1 (en) 2009-09-30 2011-04-07 Transtech Pharma, Inc. Substituted imidazole derivatives for treatment of alzheimers disease
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
WO2016005992A1 (en) * 2014-07-11 2016-01-14 Council Of Scientific And Industrial Research SUBSTITUTED NAPHTHO[2,1-b][1,10]PHENANTHROLINE BASED FLUORESCENT DYES AND APPLICATION THEREOF
US11331319B2 (en) 2017-09-28 2022-05-17 University Of Massachusetts Combination treatment for neuropsychiatric disorders
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
EP3864008A1 (de) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metaboliten von [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110493A (en) 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5677330A (en) 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
WO1994004167A1 (en) 1991-02-26 1994-03-03 THE UNITED STATES OF AMERICA represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Metal-based formulations with high microbicidal efficiency valuable for disinfection and sterilization
GB9108080D0 (en) * 1991-04-15 1991-06-05 Smithkline Beecham Plc Pharmaceutical composition
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5206264A (en) 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
GB9123937D0 (en) * 1991-11-11 1992-01-02 Framo Dev Ltd Metering device for a multiphase fluid flow
JP3277211B2 (ja) 1991-11-12 2002-04-22 プラナ・バイオテクノロジー・リミテッド アルツハイマー病の試験方法と治療方法
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
GB9211779D0 (en) 1992-06-03 1992-07-15 Ciba Geigy Ag Amine salts
US5357636A (en) * 1992-06-30 1994-10-25 Dresdner Jr Karl P Flexible protective medical gloves and methods for their use
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5840739A (en) 1992-11-16 1998-11-24 University Of Florida Research Foundation, Inc. Thiazoline acid derivatives
EP0713392A1 (de) 1994-05-11 1996-05-29 P.N. Gerolymatos S.A. VERWENDUNG VON CLIOQUINOL ZUR BEHANDLUNG DER DURCH HELICOBACTER - z.B. H. PYLOZI - VERURSACHTEN INFEKTIONEN UND ÄNLICHEN KRANKHEITEN
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
EP0815134B1 (de) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated VERBINDUNGEN MIT AGGREGATIONS-MODULIERENDEN WIRKUNG AUF DAS AMYLOiD PROTEIN
WO1997009976A2 (en) 1995-09-01 1997-03-20 Washington University Method of reducing neurotoxic injury with zinc chelators
CZ292411B6 (cs) 1996-08-13 2003-09-17 P. N. Gerolymatos S. A. Farmaceutický prostředek
DE19648272A1 (de) * 1996-11-21 1998-05-28 Emitec Emissionstechnologie Verfahren und Vorrichtung zur Bestimmung einer Zelldichte eines Wabenkörpers, insbesondere für einen Abgaskatalysator
JP2001514661A (ja) * 1997-03-11 2001-09-11 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の処置における使用のための薬剤の同定
EA002526B1 (ru) 1997-08-21 2002-06-27 П.Н.Геролиматос С.А. Применение фанхинона для лечения болезни альцгеймера
US5980914A (en) * 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
JP2001519529A (ja) 1997-10-06 2001-10-23 ザ ジェネラル ホスピタル コーポレイション 遅発性ジスキネジーを予測するために薬物をスクリーニングするための方法
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
US6323218B1 (en) 2001-11-27
CA2323458A1 (en) 1999-09-16
CA2323458C (en) 2008-01-29
WO1999045907A2 (en) 1999-09-16
AU752236B2 (en) 2002-09-12
DE69925816D1 (de) 2005-07-21
US20020082273A1 (en) 2002-06-27
DE69925816T2 (de) 2005-12-22
WO1999045907A3 (en) 2000-04-06
WO1999045907A9 (en) 2000-11-09
AU2998199A (en) 1999-09-27
EP1061923A2 (de) 2000-12-27
HK1033907A1 (en) 2001-10-05
JP2002506020A (ja) 2002-02-26
EP1061923B1 (de) 2005-06-15

Similar Documents

Publication Publication Date Title
DE69925816D1 (de) Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol
ES2248356T3 (es) Compuestos para tratar la enfermedad de alzheimer.
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
ATE334666T1 (de) Neue fettsäureanaloge zur behandlung der fettleber
DE69533813D1 (de) Formulierungen und Verfahren zur Verminderung von Hautirritationen
ATE450515T1 (de) Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE371475T1 (de) Methoden zur behandlung der hautpigmentierung
ATE299890T1 (de) Inhibitoren von gamma-secretase
DE69519577T2 (de) Prednisolonmetasulfobenzoat-zusammensetzung zur behandlung von entzündungserkrankung des darmes
DE69902154D1 (de) Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ATE188869T1 (de) Stabilisiertes sonnenschutzmittel
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE69924676D1 (de) Rotor zur Behandlung von geschmolzenem Metall
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
DE69808607D1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
ATE222298T1 (de) Verwendung von zinklegierungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties